Asphalion submits to EMA first Scientific Advice of MYOCURE project

This MYOCURE project aims at developing an innovative gene therapy platform to cure rare hereditary muscle disorders

This MYOCURE project aims at developing an innovative gene therapy platform to cure rare hereditary muscle disorders
July 12, 2017
Asphalion participated in the first Scientific Advice procedure with the European Medicines Agency (EMA) for the MYOCURE project. The meeting was arranged in order to ask the EMA some guidance to further design and elaborate two prototype adeno-associated vectors (AAV) for the treatment of two severe orphan diseases that affect children, the glycogen storage disease II (GSDII, or Pompe disease) and the myotubular myopathy (MTM). Ultimately, the MYOCURE goal is to obtain the orphan status for both products and diseases.

The meeting went through a friendly atmosphere and the result had been very positive and in agreement with what was proposed with enriching proposals given by the EMA. The attendees were: Marinee Chuah, as coordinator of the MYOCURE project, Kirsty Harper, as toxicology expert representing Envigo, and Marta Rayo Lunar and Joel Montane Mogas from Asphalion as regulatory affairs experts and organizers of the meeting.

Asphalion participates in the MYOCURE project as a regulatory partner addressing the regulatory issues related to the clinical development of the MYOCURE innovative gene therapy platform to ultimately treat patients suffering from GSDII or MTM. In particular, Asphalion develops and conducts the following activities:

-Early Scientific Advice given by EMA for the treatment of MTM and GSDII
-Orphan Drug Designation (ODD) for prototype AAV vector for the treatment of MTM
-Orphan Drug Designation (ODD) for prototype AAV vector for the treatment of GSD II
-Late Scientific Advice given by EMA including the design of clinical trial based on the prototype AAV vectors for the treatment of MTM and GSDII

The MYOCURE project brings together the expertise of a number of European groups (Spain, Belgium, France, UK, and Germany) in a number of fields required for an adequate development of the gene therapy project.

MYOCURE: This project has received funding from the European Union?s Horizon 2020 research and innovation programme under grant agreement No 667751.             

Search News & Events

  • Filter by category

Share

Related news and events

Christmas season greatings

Season’s Greetings

We wish you Happy ‘Xmas, Prosperous New Year and Health for you and your loved ones.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting